SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?


To: Keith Feral who wrote (383)6/6/2008 2:54:53 PM
From: ggamerRead Replies (1) | Respond to of 418
 
I am still holding!



To: Keith Feral who wrote (383)6/16/2008 10:03:54 AM
From: ggamerRead Replies (1) | Respond to of 418
 
ADVENTRX Pharmaceuticals (ANX) provides an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer; overall survival results in this study have been revised upwards slightly, with the CoFactor/5-FU arm demonstrating a 14 day improvement in overall survival compared to the leucovorin/5-FU arm.